Brief: CNS Doses First Group Of Patients With Berubicin In Study For Treatment Of Glioblastoma Multiforme (GBM)

CNS Pharmaceuticals

30/09/2021 13:36

Sept 30 (Reuters) - CNS Pharmaceuticals Inc  CNSP.O :
    * CNS PHARMACEUTICALS DOSES FIRST GROUP OF PATIENTS WITH
BERUBICIN, AN FDA-DESIGNATED FAST TRACK DRUG CANDIDATE, IN THE
POTENTIALLY PIVOTAL STUDY FOR THE TREATMENT OF GLIOBLASTOMA
MULTIFORME (GBM)

Source text for Eikon:  ID:nPn6rHBKta 
Further company coverage:  CNSP.O 

 ((Reuters.Briefs@thomsonreuters.com;))